Literature DB >> 2126441

IgG subclass antibodies to serogroup B meningococcal outer membrane antigens following infection and vaccination.

H Sjursen1, E Wedege, E Rosenqvist, A Naess, A Halstensen, R Matre, C O Solberg.   

Abstract

IgG and IgG subclass antibodies to the outer membrane antigens from Neisseria meningitidis (serogroup B, serotype 15:P1.16) were quantitated by an enzyme-linked immunosorbent assay (ELISA) in sera from 40 patients with group B:15:P1.16 meningococcal disease and 24 volunteers immunized with a serotype 15:P1.16 outer membrane vesicle vaccine. A second injection was given 6 weeks after the first immunization. Patient sera obtained two and six weeks after onset of the disease had significantly higher levels of total IgG, IgG1, IgG2, and IgG3 antibodies to the outer membrane antigens than acute sera, convalescent sera from patients with systemic non-meningococcal bacterial infections and sera from healthy controls. The levels of total IgG and IgG1 remained high one and three years later. Sera from the vaccinees showed high levels of total IgG and IgG1 6, 12 and 26 weeks after the first immunization and high levels of IgG3 6 weeks after the second immunization. No increase of IgG2 or IgG4 levels was observed in the postimmunization sera. Immunoblotting of three convalescent sera demonstrated individual patterns of IgG subclass binding to various outer membrane antigens with most distinct binding of IgG1 and IgG3 antibodies to the class I protein, the H.8 lipoprotein and the lipopolysaccharide. Since IgG1 and IgG3 are the most effective antibodies for complement activation and phagocytosis, group B meningococcal disease and immunization with the serotype 15:P1.16 outer membrane vesicle vaccine stimulate production of those IgG subclasses which have the strongest opsonic and bactericidal activity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2126441     DOI: 10.1111/j.1699-0463.1990.tb05035.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  13 in total

1.  Construction and functional activities of chimeric mouse-human immunoglobulin G and immunoglobulin M antibodies against the Neisseria meningitidis PorA P1.7 and P1.16 epitopes.

Authors:  Terje E Michaelsen; Øistein Ihle; Karen Johanne Beckstrøm; Tove K Herstad; Jan Kolberg; E Arne Høiby; Audun Aase
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

2.  Properdin deficiency in a large Swiss family: identification of a stop codon in the properdin gene, and association of meningococcal disease with lack of the IgG2 allotype marker G2m(n).

Authors:  P J Späth; A G Sjöholm; G N Fredrikson; G Misiano; R Scherz; U B Schaad; B Uhring-Lambert; G Hauptmann; J Westberg; M Uhlén; C Wadelius; L Truedsson
Journal:  Clin Exp Immunol       Date:  1999-11       Impact factor: 4.330

3.  Understanding the immune responses to the meningococcal strain-specific vaccine MeNZB measured in studies of infants.

Authors:  N Ruijne; R A Lea; J O'Hallahan; P Oster; D Martin
Journal:  Clin Vaccine Immunol       Date:  2006-07

4.  Functional opsonic activity of human serum antibodies to inner core lipopolysaccharide (galE) of serogroup B meningococci measured by flow cytometry.

Authors:  J S Plested; B L Ferry; P A Coull; K Makepeace; A K Lehmann; F G MacKinnon; H G Griffiths; M A Herbert; J C Richards; E R Moxon
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

5.  Potential of recombinant opa proteins as vaccine candidates against hyperinvasive meningococci.

Authors:  M J Callaghan; S Lewis; M Sadarangani; S E S Bailey; H Chan; D J P Ferguson; J P Derrick; I Feavers; M C Maiden; A J Pollard
Journal:  Infect Immun       Date:  2011-04-04       Impact factor: 3.441

6.  Serum antibody responses in Ethiopian meningitis patients infected with Neisseria meningitidis serogroup A sequence type 7.

Authors:  Gunnstein Norheim; Abraham Aseffa; Mohammed Ahmed Yassin; Getahun Mengistu; Afework Kassu; Dereje Fikremariam; Wegene Tamire; Yared Merid; E Arne Høiby; Dominique A Caugant; Elisabeth Fritzsønn; Torill Tangen; Tsegaye Alebel; Degu Berhanu; Morten Harboe; Einar Rosenqvist
Journal:  Clin Vaccine Immunol       Date:  2007-02-14

7.  Confirmation of suspicious cases of meningococcal meningitis by PCR and enzyme-linked immunosorbent assay.

Authors:  N B Saunders; D R Shoemaker; B L Brandt; W D Zollinger
Journal:  J Clin Microbiol       Date:  1997-12       Impact factor: 5.948

8.  Humoral immune response to the class 3 outer membrane protein during the course of meningococcal disease.

Authors:  H K Guttormsen; L M Wetzler; A Naess
Journal:  Infect Immun       Date:  1993-11       Impact factor: 3.441

9.  Opa protein repertoires of disease-causing and carried meningococci.

Authors:  Martin J Callaghan; Caroline Buckee; Noel D McCarthy; Ana Belén Ibarz Pavón; Keith A Jolley; Saul Faust; Stephen J Gray; Edward B Kaczmarski; Michael Levin; J Simon Kroll; Martin C J Maiden; Andrew J Pollard
Journal:  J Clin Microbiol       Date:  2008-05-28       Impact factor: 5.948

10.  Humoral immune response to class 1 outer membrane protein during the course of meningococcal disease.

Authors:  H K Guttormsen; L M Wetzler; C O Solberg
Journal:  Infect Immun       Date:  1994-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.